Frontier Capital Management Co. LLC Cuts Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Frontier Capital Management Co. LLC cut its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 0.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 73,215 shares of the medical research company’s stock after selling 133 shares during the period. Frontier Capital Management Co. LLC’s holdings in Charles River Laboratories International were worth $13,515,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in CRL. D1 Capital Partners L.P. acquired a new stake in Charles River Laboratories International in the 4th quarter valued at $172,752,000. Norges Bank acquired a new position in shares of Charles River Laboratories International during the 4th quarter worth about $98,886,000. Wellington Management Group LLP lifted its position in Charles River Laboratories International by 9.0% during the fourth quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company’s stock worth $752,508,000 after buying an additional 335,658 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Charles River Laboratories International in the 4th quarter valued at $42,776,000. Finally, Alyeska Investment Group L.P. acquired a new stake in shares of Charles River Laboratories International in the 4th quarter worth $36,968,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Wall Street Analyst Weigh In

CRL has been the subject of several recent analyst reports. Barclays raised their price objective on shares of Charles River Laboratories International from $145.00 to $155.00 and gave the stock an “equal weight” rating in a research report on Thursday. Redburn Atlantic upgraded Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price objective on the stock in a report on Monday, March 3rd. Citigroup raised Charles River Laboratories International from a “sell” rating to a “neutral” rating and raised their target price for the stock from $155.00 to $175.00 in a research note on Tuesday, March 4th. The Goldman Sachs Group cut Charles River Laboratories International from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $190.00 to $170.00 in a report on Friday, March 21st. Finally, William Blair lowered shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $176.00.

Insider Activity at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 4,400 shares of the firm’s stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the transaction, the executive vice president now owns 20,013 shares in the company, valued at $3,252,112.50. This trade represents a 18.02 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Birgit Girshick acquired 1,514 shares of Charles River Laboratories International stock in a transaction on Thursday, February 20th. The stock was purchased at an average price of $164.63 per share, with a total value of $249,249.82. Following the purchase, the chief operating officer now owns 55,058 shares of the company’s stock, valued at $9,064,198.54. The trade was a 2.83 % increase in their position. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Stock Performance

Shares of CRL opened at $141.59 on Friday. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $254.15. The stock has a market capitalization of $6.95 billion, a PE ratio of 943.95, a PEG ratio of 4.54 and a beta of 1.50. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. The stock has a 50-day simple moving average of $138.92 and a 200-day simple moving average of $166.78.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.06 by $0.28. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business had revenue of $984.17 million during the quarter, compared to analysts’ expectations of $942.34 million. During the same period in the previous year, the company earned $2.27 EPS. The company’s revenue for the quarter was down 2.7% on a year-over-year basis. On average, analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).